BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29040544)

  • 1. Mutation-specific downregulation of CFTR2 variants by gating potentiators.
    Avramescu RG; Kai Y; Xu H; Bidaud-Meynard A; Schnúr A; Frenkiel S; Matouk E; Veit G; Lukacs GL
    Hum Mol Genet; 2017 Dec; 26(24):4873-4885. PubMed ID: 29040544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Gating by Two Chemically Distinct Potentiators, Ivacaftor (VX-770) and 5-Nitro-2-(3-Phenylpropylamino) Benzoate.
    Lin WY; Sohma Y; Hwang TC
    Mol Pharmacol; 2016 Sep; 90(3):275-85. PubMed ID: 27413118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cigarette smoke activates CFTR through ROS-stimulated cAMP signaling in human bronchial epithelial cells.
    Wong FH; AbuArish A; Matthes E; Turner MJ; Greene LE; Cloutier A; Robert R; Thomas DY; Cosa G; Cantin AM; Hanrahan JW
    Am J Physiol Cell Physiol; 2018 Jan; 314(1):C118-C134. PubMed ID: 28978522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorescence assay for simultaneous quantification of CFTR ion-channel function and plasma membrane proximity.
    Prins S; Langron E; Hastings C; Hill EJ; Stefan AC; Griffin LD; Vergani P
    J Biol Chem; 2020 Dec; 295(49):16529-16544. PubMed ID: 32934006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle.
    Jih KY; Hwang TC
    Proc Natl Acad Sci U S A; 2013 Mar; 110(11):4404-9. PubMed ID: 23440202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1-BENZYLSPIRO[PIPERIDINE-4,1'-PYRIDO[3,4-b]indole] 'co-potentiators' for minimal function CFTR mutants.
    Son JH; Phuan PW; Zhu JS; Lipman E; Cheung A; Tsui KY; Tantillo DJ; Verkman AS; Haggie PM; Kurth MJ
    Eur J Med Chem; 2021 Jan; 209():112888. PubMed ID: 33092904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-derived cell models for personalized medicine approaches in cystic fibrosis.
    Ramalho AS; Amato F; Gentzsch M
    J Cyst Fibros; 2023 Mar; 22 Suppl 1(Suppl 1):S32-S38. PubMed ID: 36529661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional correction of CFTR mutations in human airway epithelial cells using adenine base editors.
    Krishnamurthy S; Traore S; Cooney AL; Brommel CM; Kulhankova K; Sinn PL; Newby GA; Liu DR; McCray PB
    Nucleic Acids Res; 2021 Oct; 49(18):10558-10572. PubMed ID: 34520545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring intrinsic variability between cultured nasal and bronchial epithelia in cystic fibrosis.
    Rodenburg LW; Metzemaekers M; van der Windt IS; Smits SMA; den Hertog-Oosterhoff LA; Kruisselbrink E; Brunsveld JE; Michel S; de Winter-de Groot KM; van der Ent CK; Stadhouders R; Beekman JM; Amatngalim GD
    Sci Rep; 2023 Oct; 13(1):18573. PubMed ID: 37903789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A common mechanism for CFTR potentiators.
    Yeh HI; Sohma Y; Conrath K; Hwang TC
    J Gen Physiol; 2017 Dec; 149(12):1105-1118. PubMed ID: 29079713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bypassing CFTR dysfunction in cystic fibrosis with alternative pathways for anion transport.
    Li H; Salomon JJ; Sheppard DN; Mall MA; Galietta LJ
    Curr Opin Pharmacol; 2017 Jun; 34():91-97. PubMed ID: 29065356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correcting CFTR folding defects by small-molecule correctors to cure cystic fibrosis.
    Mijnders M; Kleizen B; Braakman I
    Curr Opin Pharmacol; 2017 Jun; 34():83-90. PubMed ID: 29055231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corrector combination therapies for F508del-CFTR.
    Hanrahan JW; Matthes E; Carlile G; Thomas DY
    Curr Opin Pharmacol; 2017 Jun; 34():105-111. PubMed ID: 29080476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.
    Taylor-Cousar JL; Munck A; McKone EF; van der Ent CK; Moeller A; Simard C; Wang LT; Ingenito EP; McKee C; Lu Y; Lekstrom-Himes J; Elborn JS
    N Engl J Med; 2017 Nov; 377(21):2013-2023. PubMed ID: 29099344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystic fibrosis transmembrane regulator haplotypes in households of patients with cystic fibrosis.
    Furgeri DT; Marson FAL; Correia CAA; Ribeiro JD; Bertuzzo CS
    Gene; 2018 Jan; 641():137-143. PubMed ID: 29054758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CFTR potentiators: from bench to bedside.
    Jih KY; Lin WY; Sohma Y; Hwang TC
    Curr Opin Pharmacol; 2017 Jun; 34():98-104. PubMed ID: 29073476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ion channels as targets to treat cystic fibrosis lung disease.
    Martin SL; Saint-Criq V; Hwang TC; Csanády L
    J Cyst Fibros; 2018 Mar; 17(2S):S22-S27. PubMed ID: 29102290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.
    Rowe SM; Daines C; Ringshausen FC; Kerem E; Wilson J; Tullis E; Nair N; Simard C; Han L; Ingenito EP; McKee C; Lekstrom-Himes J; Davies JC
    N Engl J Med; 2017 Nov; 377(21):2024-2035. PubMed ID: 29099333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The implications of CFTR structural studies for cystic fibrosis drug development.
    Callebaut I; Hoffmann B; Mornon JP
    Curr Opin Pharmacol; 2017 Jun; 34():112-118. PubMed ID: 29096277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation.
    Trimble AT; Donaldson SH
    J Cyst Fibros; 2018 Mar; 17(2):e13-e16. PubMed ID: 29079142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.